Control Of The Ras/Erk Signaling Pathway By The Brahma Chromatin-remodeling Complex
Funder
National Health and Medical Research Council
Funding Amount
$524,820.00
Summary
Hormones bind and initiate molecular signals within cells to proliferate or change into specific cell types. This is important for growth and development of different tissues. A pathway which is critical for transmitting the effects of hormones in cells is the Ras pathway. New studies by the applicants indicate that the Brahma complex, a molecule important in controlling the levels of proteins in cells, activates the Ras pathway. This project will define how Brahma controls the Ras pathway.
Engineering MYCN Models Of High-grade Serous Ovarian Cancer (HGSC)
Funder
National Health and Medical Research Council
Funding Amount
$797,478.00
Summary
The most lethal type of ovarian cancer, high-grade serous cancer (HGSC), can be divided into four subtypes based on gene patterns. One subtype involves a set of genes/proteins that, in their specific combination, result in activation of a pathway known as MYCN. As most HGSC start in the fallopian tube, we are using fallopian tube material to make new MYCN HGSC models to observe development in the earliest stages. We hope to generate new tests and treatments for this subtype of ovarian cancer.
New Treatments For Epitheliod Inflammatory Myofibroblastic Sarcoma
Funder
National Health and Medical Research Council
Funding Amount
$647,267.00
Summary
Epithelioid Inflammatory myofibroblastic sarcoma (eIMS) is a rare aggressive cancer, most common in of childhood and young adults. This cancer has been scarcely studied due to its rarity and is not cured by standard chemotherapeutic regimes. Our investigations will extensively characterise eIMS samples from recently diagnosed patients, and apply a new laboratory model to discover more effective drugs and improve treatment outcomes.
Characterization Of Ras-Stimulated Macropinocytosis In Pancreatic Cancer
Funder
National Health and Medical Research Council
Funding Amount
$470,964.00
Summary
Pancreatic cancer (PC) is one of the most lethal human cancers, namely due to frequent late stage diagnosis. Thus, there is urgent need to better understand the biology of this disease. Cancer cells are characteristically more reliant on nutrients in order to sustain their growth, making them more vulnerable to inhibition of nutrient supplies. The key aim of this project is to better understand the ways in which PC cells take up nutrients so that these processes may potentially be blocked.
Therapeutic Targeting Of MYCN Oncoprotein Stability In Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$590,206.00
Summary
A high level of MYCN protein is a major indicator of aggressive neuroblastoma (NB) but unfortunately there have been many barriers to the design of targeted therapies. We have identified a protein called PA2G4 which is a cofactor for MYCN in promoting cancer cell growth. We have developed a compound which inhibits PA2G4 and MYCN protein levels and reduces tumour growth. We will examine how PA2G4 cause aggressive tumour characteristics and test new methods to block PA2G4.
Understanding The Role Of RAS Mutations In Thyroid Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$463,854.00
Summary
My fellowship will examine the association of RAS mutations in thyroid cancer. RAS proteins are the most mutated in cancer and I will investigate how they work in thyroid cancer. RAS mutated thyroid cancer is more likely to cause death. This grant will be based in the pioneering lab of Prof Fagin at Memorial Sloan Kettering Cancer Center and the Garvan Institute of Medical Research. It is hoped by understanding these mutations, new treatments for thyroid cancer can be developed.
Treatments that target cancer causing genes called oncogenes have resulted in new treatment paradigms for cancer. We suggest that outcomes of patients with cancer will be further substantially improved by understanding how cancers can overcome resistance to these treatments that develops in many patients. To accelerate the adoption of these and other new treatments for cancer we will also develop new frameworks for clinical trials.
The Mutational Landscape Of Melanoma In Adolescents And Young Adults
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Melanoma is the most common cause of cancer mortality in 20-34 year olds and many traditional treatments, chemotherapy and radiotherapy cause tremendous long-term damage to growing bodies. Fortunately new drugs that target the genetic mutations are proving effective. Unfortunately, the genomic mutation specific to young melanoma patients are unknown. This study aims to characterising the genomic mutations of young melanoma patients, leading to the discovery of innovative treatment options.